Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02811653

Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease

In AD (Alzheimer disease), the anatomic correlates of attention disorders (as evaluated by motor slowing) have not been thoroughly characterized.

Recruiting

Interested in participating?

Request Info

Key information

Age range

40 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients
  • Age between 40 and 85
  • French mother tongue
  • Consulting at the Amiens Memory Resource and Research Centre (CMRR) for:
  • MCI, according to Albert et al.'s criteria (Albert et al., 2011)
  • Mild dementia (MMSE>20) due to AD, according to McKhann's criteria (McKhann et al., 2011).
  • Mild dementia due to LBD, according to McKeith et al.'s criteria (McKeith et al., 2005).
  • Mild dementia due to FTLD, according to Rascovsky et al.'s criteria (Rascovsky et al., 2011).
  • Social security coverage
  • Healthy controls
  • Healthy age and gender matched volunteers will be recruited into the study from the general population.

Exclusion criteria

  • Reading or writing difficulties related to a learning disorder or illiteracy.
  • A medical history with a potentially significant impact on cognition (non-corrected thyroid disorders or heart failure):
  • NYHA stage IV dyspnoea.
  • respiratory impairment requiring oxygen therapy.
  • liver impairment.
  • kidney failure, progressing neoplastic disease, or past or present alcohol abuse.
  • Past or present neurological disorders other than those having prompted consultation in the Memory Clinic:
  • stroke.
  • meningitis or encephalitis.
  • severe head injury.
  • sensorimotor impairments (sensory, proprioceptive, cerebellar and visual impairments).
  • epilepsy (requiring ongoing treatment),
  • psychiatric disorders (other than treated depression).
  • treatment with psychotropic medications (other than anxiolytics or antidepressant withdrawn or initiated in the previous month). Patients with parkinsonian syndrome were examined in the "on-drug" state.
  • Impossibility to perform a neuropsychological evaluation or brain MRI.
  • Withdrawal from the study at any time, if desired.
  • Pregnancy
  • Contra-indication to MRI:
  • nerve stimulators
  • cochlear implants
  • ferromagnetic foreign bodies close to nervous structures in the eye or brain
  • cerebral shunts
  • dental appliances
  • Legal guardianship or incarceration.

Treatment and study plan

Brain MRI

Device

Neuropsychological evaluation

Other

Blood

Biological

Primary outcomes

  1. median SRT (simple reaction time) to a stimulus (in milliseconds)

    Time frame: Day 0

Study contacts

Contact information is provided by the study sponsor or research team.

Daniela ANDRIUTA, PhD

CONTACT

[email protected]

+33 3 22 66 82 40

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire, Amiens

Other

Registry information

Acronym: TAMA

Important dates

Study start
2015
Primary completion
2028
Study completion
2028
First posted
Jun 23, 2016
Registry last updated
May 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.